check_circleStudy Completed

Hormone replacement therapy (HRT)

Angeliq low/low: Relative Bioavailability

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 75 Years
  • -

  • -

Trial summary

Enrollment Goal
18
Trial Dates
June 2009 - September 2009
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Low-Dose E2/DRSP (BAY86-4891)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Pharma AGBerlin, 13353, Germany

Trial design

Open-label, randomized, crossover study to investigate the relative bioavailability of estradiol (E2) and drospirenone (DRSP) after single oral administration of a tablet containing 0.5 mg E2 + 0.5 mg DRSP, a tablet containing 0.5 mg E2 + 0.25 mg DRSP and a microcrystalline suspension containing 0.5 mg E2 + 0.5 mg DRSP in 18 healthy postmenopausal women
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A